# Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT

> **NCT05468229** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese University of Hong Kong** · enrollment: 20 (estimated)

## Conditions studied

- Glucose Intolerance

## Interventions

- **DRUG:** Dorzagliatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05468229
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08
- **Primary completion:** 2023-04
- **Final completion:** 2023-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468229, "Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05468229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*